MX2020012656A - Lopinavir y ritonavir para el tratamiento de trastornos del cuello uterino. - Google Patents

Lopinavir y ritonavir para el tratamiento de trastornos del cuello uterino.

Info

Publication number
MX2020012656A
MX2020012656A MX2020012656A MX2020012656A MX2020012656A MX 2020012656 A MX2020012656 A MX 2020012656A MX 2020012656 A MX2020012656 A MX 2020012656A MX 2020012656 A MX2020012656 A MX 2020012656A MX 2020012656 A MX2020012656 A MX 2020012656A
Authority
MX
Mexico
Prior art keywords
lopinavir
ritonavir
treatment
cervical disorders
cervical
Prior art date
Application number
MX2020012656A
Other languages
English (en)
Spanish (es)
Inventor
Ian Hampson
Lynne Hampson
Original Assignee
Douglas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Douglas Pharmaceuticals Ltd filed Critical Douglas Pharmaceuticals Ltd
Publication of MX2020012656A publication Critical patent/MX2020012656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2020012656A 2018-05-24 2019-05-23 Lopinavir y ritonavir para el tratamiento de trastornos del cuello uterino. MX2020012656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1808564.7A GB201808564D0 (en) 2018-05-24 2018-05-24 Treatments
PCT/IB2019/054292 WO2019224779A1 (en) 2018-05-24 2019-05-23 Lopinavir and ritonavir for the treatment of cervix disorders

Publications (1)

Publication Number Publication Date
MX2020012656A true MX2020012656A (es) 2021-02-02

Family

ID=62812406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012656A MX2020012656A (es) 2018-05-24 2019-05-23 Lopinavir y ritonavir para el tratamiento de trastornos del cuello uterino.

Country Status (12)

Country Link
US (2) US11738024B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801509A1 (cg-RX-API-DMAC7.html)
JP (1) JP7344911B2 (cg-RX-API-DMAC7.html)
CN (1) CN112203656B (cg-RX-API-DMAC7.html)
AU (1) AU2019274812B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020023964A2 (cg-RX-API-DMAC7.html)
CA (1) CA3100425A1 (cg-RX-API-DMAC7.html)
GB (1) GB201808564D0 (cg-RX-API-DMAC7.html)
MX (1) MX2020012656A (cg-RX-API-DMAC7.html)
SG (1) SG11202010138WA (cg-RX-API-DMAC7.html)
WO (1) WO2019224779A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006324B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) * 2019-11-27 2020-01-08 Pharmaceutic compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
ES2676151T3 (es) 2000-01-19 2018-07-17 Abbvie Inc. Formulaciones farmacéuticas mejoradas
US20020198160A1 (en) 2001-05-01 2002-12-26 Everitt Elizabeth A. Compositions and methods for enhancing the bioavailability of pharmaceutical agents
US20030129208A1 (en) 2002-01-07 2003-07-10 Alberts David S. Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses
US20040167139A1 (en) 2002-07-26 2004-08-26 Potter David A. Methods of treating cancer
BR0302523A (pt) 2003-07-23 2005-04-05 Cristalia Prod Quimicos Farm Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2582559A1 (en) 2003-11-28 2005-06-16 The University Of Manchester Treatment of hpv infections and cancer
US9005889B2 (en) 2007-01-16 2015-04-14 The Johns Hopkins University Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor
JP2011518184A (ja) 2008-04-18 2011-06-23 ナノバイオ コーポレーション ヘルペスウイルス感染の治療方法
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
KR20130139896A (ko) 2010-09-08 2013-12-23 프로노바 바이오파마 너지 에이에스 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물
GB201115635D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
CN102614114B (zh) 2012-04-26 2013-10-02 河南中医学院 一种维生素e自乳化软膏
WO2014143127A1 (en) 2013-03-15 2014-09-18 Differential Drug Development Associates Llc Emulsion formulations
WO2015059485A1 (en) * 2013-10-23 2015-04-30 The University Of Manchester Treatment of cancer and benign proliferative disorders
WO2016123541A2 (en) 2015-01-30 2016-08-04 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of encephalitis infection
WO2019130341A1 (en) 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201808567D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201808571D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
GB201907305D0 (en) 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
GB201917252D0 (en) 2019-11-27 2020-01-08 Pharmaceutic compositions

Also Published As

Publication number Publication date
US20240148729A1 (en) 2024-05-09
AU2019274812A1 (en) 2020-12-10
WO2019224779A1 (en) 2019-11-28
GB201808564D0 (en) 2018-07-11
ZA202006324B (en) 2022-01-26
CN112203656B (zh) 2024-09-27
CA3100425A1 (en) 2019-11-28
SG11202010138WA (en) 2020-11-27
JP2021525266A (ja) 2021-09-24
US11738024B2 (en) 2023-08-29
US20210213015A1 (en) 2021-07-15
BR112020023964A2 (pt) 2021-02-23
JP7344911B2 (ja) 2023-09-14
US12678439B2 (en) 2026-07-14
EP3801509A1 (en) 2021-04-14
CN112203656A (zh) 2021-01-08
AU2019274812B2 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
MX2020011196A (es) Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.
MX2021004431A (es) Procesos novedosos.
MX2020009235A (es) Formulacion oftalmica.
MX2019012676A (es) Derivados de 2-aminoquinolina.
MA30597B1 (fr) Utilisation d'une matrice hydrophile comportant un derive de l'acide polyacrylique, un ether de cellulose et un delitant pour la fabrication d'un medicament destine a traiter des troubles genitaux feminins
MX2020012622A (es) Tratamientos.
JP2012515170A5 (cg-RX-API-DMAC7.html)
MX2023001445A (es) Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.
PH12019501900A1 (en) Treatment of hidradenitis suppurativa
IL286677A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
FI3177281T3 (fi) Rasvahappojen ja palmitoyylietanoliamidin seos käytettäväksi tulehduksellisten ja allergisten patologioiden hoitoon
ZA202006324B (en) Lopinavir and ritonavir for the treatment of cervix disorders
MA53010B1 (fr) Formulations d'un inhibiteur de axl/mer
PH12022551177A1 (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
IL286688A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201911868D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3762006C0 (en) KRILL OIL FOR SOLUBILIZATION OF PARTLY WATER SOLUBLE FOOD SUPPLEMENTS AND PHARMACEUTICAL INGREDIENTS
AU2021242808A8 (en) Solid dispersions of amorphous 3, 4-diphenyl-4, 5-dihydro- 1H-pyrazole derivatives, compositions comprising them and uses thereof as cannabinoid CB1 receptor inhibitors
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
EP4005635A4 (en) AGENTS FOR REGULATION OF FEMALE HORMONES SECRETION AND AGENTS FOR RELIEF OF UNPLEASANT SYMPTOMS
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
HRP20190211T1 (hr) Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti